{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:37:50Z","timestamp":1793036270899,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81970188"],"award-info":[{"award-number":["No. 81970188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["No.7202154"],"award-info":[{"award-number":["No.7202154"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund","award":["2016-12M-1-001"],"award-info":[{"award-number":["2016-12M-1-001"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-134"],"award-info":[{"award-number":["2022-PUMCH-B-134"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05708-w","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T01:01:45Z","timestamp":1716858105000},"page":"3061-3069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China"],"prefix":"10.1007","volume":"103","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-5965","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-ping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-huan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-shun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-qin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-lai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-mei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-nan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng-jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-xia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. A.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"issue":"12","key":"5708_CR1","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117(12):3402\u20133408. https:\/\/doi.org\/10.1182\/blood-2010-09-310342","journal-title":"Blood"},{"issue":"5","key":"5708_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.14477","volume":"176","author":"D Chihara","year":"2017","unstructured":"Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ et al (2017) The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750\u2013758. https:\/\/doi.org\/10.1111\/bjh.14477","journal-title":"Br J Haematol"},{"issue":"4","key":"5708_CR3","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/annonc\/mdl466","volume":"18","author":"J Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez J, Conde E, Guti\u00e9rrez A, Arranz R, Le\u00f3n A, Mar\u00edn J et al (2007) The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish lymphoma and autologous transplantation group experience. Ann Oncol 18(4):652\u2013657. https:\/\/doi.org\/10.1093\/annonc\/mdl466","journal-title":"Ann Oncol"},{"issue":"1","key":"5708_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/jco.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106\u2013113. https:\/\/doi.org\/10.1200\/jco.2008.17.4870","journal-title":"J Clin Oncol"},{"issue":"25","key":"5708_CR5","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/jco.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H et al (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30(25):3093\u20133099. https:\/\/doi.org\/10.1200\/jco.2011.40.2719","journal-title":"J Clin Oncol"},{"issue":"23","key":"5708_CR6","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/jco.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J et al (2015) Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33(23):2492\u20132499. https:\/\/doi.org\/10.1200\/jco.2014.59.2782","journal-title":"J Clin Oncol"},{"issue":"6","key":"5708_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/jco.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631\u2013636. https:\/\/doi.org\/10.1200\/jco.2011.37.4223","journal-title":"J Clin Oncol"},{"issue":"8","key":"5708_CR8","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26(8):1766\u20131771. https:\/\/doi.org\/10.1093\/annonc\/mdv237","journal-title":"Ann Oncol"},{"issue":"1","key":"5708_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/hematology.2019000012","volume":"2019","author":"N Mehta-Shah","year":"2019","unstructured":"Mehta-Shah N (2019) Emerging strategies in peripheral T-cell lymphoma. Hematol Am Soc Hematol Educ Program 2019(1):41\u201346. https:\/\/doi.org\/10.1182\/hematology.2019000012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"5708_CR10","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1080\/10428190802455867","volume":"49","author":"AN Abouyabis","year":"2008","unstructured":"Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR (2008) Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 49(11):2099\u20132107. https:\/\/doi.org\/10.1080\/10428190802455867","journal-title":"Leuk Lymphoma"},{"key":"5708_CR11","doi-asserted-by":"publisher","unstructured":"d\u2019Amore F, Gaulard P, Tr\u00fcmper L, Corradini P, Kim WS, Specht L et al (2015) Peripheral T-cell lymphomas: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26 Suppl 5v108\u2013115. https:\/\/doi.org\/10.1093\/annonc\/mdv201","DOI":"10.1093\/annonc\/mdv201"},{"issue":"11","key":"5708_CR12","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C et al (2017) Clinical practice recommendations on indication and timing of Hematopoietic Cell Transplantation in Mature T Cell and NK\/T Cell Lymphomas: an International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and marrow transplantation. Biol Blood Marrow Transpl 23(11):1826\u20131838. https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.027","journal-title":"Biol Blood Marrow Transpl"},{"key":"5708_CR13","unstructured":"NCCN guideline for TCL (2020) NCCN Clinical Practice Guidelines in T cell lymphoma (2020 Version I). http:\/\/www.nccn.org"},{"key":"5708_CR14","doi-asserted-by":"publisher","first-page":"875469","DOI":"10.3389\/fonc.2022.875469","volume":"12","author":"W Guo","year":"2022","unstructured":"Guo W, Wang X, Li J, Yin X, Zhao Y, Tang Y et al (2022) Chidamide Maintenance Therapy Following Induction Therapy in patients with peripheral T-Cell Lymphoma who are Ineligible for autologous stem cell transplantation: Case Series from China. Front Oncol 12:875469. https:\/\/doi.org\/10.3389\/fonc.2022.875469","journal-title":"Front Oncol"},{"key":"5708_CR15","doi-asserted-by":"publisher","first-page":"835103","DOI":"10.3389\/fimmu.2022.835103","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Su N, Fang Y, Ma S, Zhang Y, Cai J et al (2022) Comparison of Chemotherapy Combined with Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma. Front Immunol 13:835103. https:\/\/doi.org\/10.3389\/fimmu.2022.835103","journal-title":"Front Immunol"},{"issue":"4","key":"5708_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1600-0609.2007.00815.x","volume":"78","author":"J Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez J, Conde E, Guti\u00e9rrez A, Arranz R, Gandarillas M, Leon A et al (2007) Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 78(4):290\u2013296. https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00815.x","journal-title":"Eur J Haematol"},{"issue":"6","key":"5708_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00277-013-1685-5","volume":"92","author":"JS Ahn","year":"2013","unstructured":"Ahn JS, Yang DH, Jung SH, Chae YS, Sohn SK, Yhim HY et al (2013) Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. Ann Hematol 92(6):789\u2013797. https:\/\/doi.org\/10.1007\/s00277-013-1685-5","journal-title":"Ann Hematol"},{"issue":"25","key":"5708_CR18","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/jco.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS et al (2013) Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma. J Clin Oncol 31(25):3100\u20133109. https:\/\/doi.org\/10.1200\/jco.2012.46.0188","journal-title":"J Clin Oncol"},{"issue":"6","key":"5708_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3760\/cma.j.issn.0253-2727.2015.06.002","volume":"36","author":"D Zou","year":"2015","unstructured":"Zou D, Huang W, Liu H, Fu M, Li Z, Sui W et al (2015) [Clinical analysis of 25 patients with aggressive peripheral T-cell lymphoma in advanced stage treated with autologous stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 36(6):455\u2013459. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2015.06.002","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"5708_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez J, Conde E, Guti\u00e9rrez A, Arranz R, Le\u00f3n A, Mar\u00edn J et al (2007) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the gel-tamo Study Group. Eur J Haematol 79(1):32\u201338. https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00856.x","journal-title":"Eur J Haematol"},{"issue":"1","key":"5708_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/0300060516676725","volume":"45","author":"X Han","year":"2017","unstructured":"Han X, Zhang W, Zhou D, Ruan J, Duan M, Zhu T et al (2017) Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: a single-centre experience. J Int Med Res 45(1):290\u2013302. https:\/\/doi.org\/10.1177\/0300060516676725","journal-title":"J Int Med Res"},{"issue":"10168","key":"5708_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R et al (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393(10168):229\u2013240. https:\/\/doi.org\/10.1016\/s0140-6736(18)32984-2","journal-title":"Lancet"},{"issue":"15","key":"5708_CR23","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","volume":"126","author":"C Wang","year":"2015","unstructured":"Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A et al (2015) IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 126(15):1741\u20131752. https:\/\/doi.org\/10.1182\/blood-2015-05-644591","journal-title":"Blood"},{"issue":"1","key":"5708_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/leu.2014.261","volume":"29","author":"JH Schatz","year":"2015","unstructured":"Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning MA, Viale A, Huberman K et al (2015) Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. Leukemia 29(1):237\u2013241. https:\/\/doi.org\/10.1038\/leu.2014.261","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05708-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T02:07:45Z","timestamp":1722046065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05708-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5708"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05708-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The chidamide maintenance or ASCT consolidation was selected by the treating physicians. This study was carried out in accordance with the principles of good clinical practice and the Declaration of Helsinki. The protocol, informed consent forms, and other relevant study documentation were approved by the ethics committees of all the participating centers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}